Severe valproic acid poisoning;Intoxications graves par l'acide valproïque

Reanimation

Volumn 13, Issue 5, 2004, Pages 324-333

  Bedry R ^a   Parrot, F ^b  

^a Clinique Mutualiste   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Acide valpro que; Carnitine; Hyperammoniemia; Hyperammoni mie; Intoxication; Physiopathologie; Physiopathology; Valpro c acid

Indexed keywords

CARNITINE; FATTY ACID; VALPROIC ACID;

DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY ACID TRANSPORT; HUMAN; HYPERAMMONEMIA; HYPERLACTATEMIA; INTOXICATION; METABOLIC DISORDER; MORTALITY; OXIDATION; RANDOMIZATION; REVIEW; UNITED STATES;

EID: 3042711400     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2004.03.014     Document Type: Short Survey

References (57)

1. Bolanos J.P., Medina J.M. Mini review. Effect of valproate on the metabolism of the central nervous system. Life Sci. 60:1997;1933-1942
2. Spiller A.H., Krenzelok E.P., Klein-Schwarz W., Winter M.L., Weber J.A., Sollee D.R., et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clin Toxicol. 38:2000;755-760
3. Litovitz T.L., Klein-Schwartz W., White S., Cobaugh D.J., Youniss J., Omslaer J.C., et al. 2000. Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 19:2001;337-395
4. Bourrier P., Varache N., Alquier P., Rabier D., Kamoun P., Lorre G., et al. Œdème cérébral avec hyperammoniémie au cours d'une intoxication par le valpromide. Presse Med. 17:1988;2063-2066
5. König A., Siemens H., Bläker F., Boenigk E., Gross-Selbeck G., Hanefeld F. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia. 35:1994;1005-1015
6. Fischer J.H., Barr A.N., Paloucek F.P., Dorociak J.V., Spunt A.L. Effect of food on the serum concentration profile of enteric-coated valproic acid. Neurology. 38:1988;1319-1322
7. Klotz U., Antonin K.H. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther. 21:1977;736-743
8. De Vivo D.C., Tein I. Primary and secondary disorders of carnitine metabolism. Int Pediatr. 5:1990;134-141
9. Jacob C., Belleville F. L-carnitine: métabolisme, fonctions et intérêt en pathologie. Pathol Biol. 40:1992;910-919
10. Van Wouwe J.P. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res. 65:1995;211-214
11. e édition Principes de biochimie. 1994;479-505 Médecine-Sciences Flammarion, New York
12. Li J., Norwood D.L., Mao L.F., Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry. 30:1991;388-394
13. Silva M.F., Ruiter J.P., Overmars H., Bootsma A.H., Van Gennip A.H., Jacdos C., et al. Complete beta-oxydation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J. 262:2002;755-760
14. Murakami K., Sugimoto T., Nishida N., Kobayashi Y., Kuhara T., Matsumoto I. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy. Brain Dev. 14:1992;178-181
15. Sugimoto T., Muro H., Woo M., Nishida N., Murikami K. Metabolite profiles in patients on high-dose valproate monotherapy. Epilepsy Research. 25:1996;107-112
16. Coulter D.L. Carnitine, valproate, and toxicity. J Child Neurol. 6:1991;7-14
17. Hiraoka A., Arato T., Tominaga I. Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs. Biol Pharm Bull. 20:1997;91-93
18. Sugimoto T., Muro H., Woo M., Murakami K., Nishida N., Sasaki T. Significance of the administration of L-carnitine with valproate therapy: determination of urinary valproylcarnitine. No To Hattatsu. 27:(suppl):1995;S129
19. Hirose S., Mitsudome A., Yasumoto S., Ogawa A., Muta Y., Tomoda Y. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics. 5:1998;1-5
20. Camina M.F., Rozas I., Castro-Gago M., Paz J.M., Alonso C., Rodriguez-Segade S. Alteration of renal carnitine metabolism by anticonvulsant treatment. Neurology. 41:1991;1444-1448
21. Mortensen P.B., Hansen H.E., Pedersen B., Hartmann-Andersen F., Husted S.E. Acute valproate intoxication: biochemical investigations and haemodialysis treatment. Int J Clin Pharmacol Ther Toxicol. 21:1983;64-68
22. Andersen G.O., Ritland S. Life threatening intoxication with sodium valproate. Clin Toxicol. 33:1995;279-284
23. Loscher W., Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther. 226:1983;845-854
24. Dupuis R.E., Lichtman S.N., Pollack G.M. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf. 5:1990;65-71
25. Sugimoto T., Araki A., Nishida N., Sakane Y., Woo M., Takeuchi T. Hepatotoxicity in rat following administration of valproic acid: effect of L-carnitine supplementation. Epilepsia. 28:1987;373-377
26. Thurston J.H., Hauhart R.E. Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme-A metabolism by cotreatment with panthothenate and carnitine in developing mice: possible clinical significance. Pediatr Res. 31:1992;419-423
27. Triggs W.J., Bohan T.P., Lin S.N., Willmore L.J. Valproate-induced coma with ketosis and carnitine insufficiency. Arch Neurol. 47:1990;1131-1133
28. Baillie J., Baillie T.A. Incidental microvesicular steatosis due to valproic acid anticonvulsivant therapy. Am J Gastroenterol. 87:1992;1225-1226
29. Sugimoto T., Muro H., Woo M., Nishida N., Murikami K. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia. 37:1996;1200-1203
30. Levy R.H., Rettenmeier A.W., Anderson G.D., Wilensky A.J., Friel P.N., Baillie T.A., et al. Effects of the polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther. 48:1990;225-235
31. Beghi E., Bizzi A., Codegoni A.M., Trevisan D., Torri W. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia. 31:1990;346-352
32. Marini A.M., Zaret B.S., Randolph Beckner R. Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology. 38:1988;365-371
33. Lam C.W., Lau C.H., Williams J.C., Chan Y.W., Wong L.J.C. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 156:1997;562-564
34. Martin G., Michoudet C., Baverel G. Stimulation of glutamine metabolism by the antiepileptic drug, sodium valproate, in isolated dog kidney tubules. Bioch Pharmacol. 38:1989;3947-3952
35. Dumoulin A., Lapostolle F., Adnet F., Muzynski J., Baud F.J. Acidose et hyperlactatémie lors des intoxications aiguës par le valproate de sodium. Presse Med. 26:1997;555-557
36. Johnson D.W., Harrison J.R., Norton W.A., Poulos A., Robertson E.F. Plasma cis-dec-4-enoic acid measured by isotope dilution mass spectrometry; an improved assay to diagnose medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 17:1994;554-559
37. Litovitz T.L., Felberg L., White S., Klein-Schwartz W. 1995 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 14:1996;487-537
38. ®). Intérêt de la supplémentation en carnitine. Réan Urg. 6:1997;771. (abstract)
39. Eeg-Olofsson O., Lindskog U. Acute intoxication with valproate. Lancet. 2:1982;1306
40. Karlsen R.L., Kett K., Henriksen O. Intoxication with sodium valproate. A case-report. Acta Med Scand. 213:1983;405-406
41. Fernandez M.C., Walter F.G., Peterson L.R., Walkotte S.M. Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. Clin Toxicol. 34:1996;437-439
42. Triggs W.J., Gilmore R.L., Millington D.S., Cibula J., Bunch T.S., Harman E. Valproate-associated carnitine deficiency and malignant cerebral oedema in the absence of hepatic failure. Int J Clin Pharmacol Ther. 35:1997;353-356
43. Sztajnkrycer D. Valproic acid toxicity: overview and management. Clin Toxicol. 40:2002;789-801
44. Schnabel R., Rambeck B., Janssen F. Fatal intoxication with sodium valproate. Lancet. 1:1984;221-222
45. Khoo S.H., Leyland M.J. Cerebral oedema following acute sodium valproate overdose. J Toxicol Clin Toxicol. 30:1992;209-214
46. Berthelot-Moritz F., Chadda K., Chanavaz I., Leroy J.P., Droy J.M., Bonmarchand G., et al. Fatal sodium valproate poisoning. Intensive Care Med. 23:1997;599
47. Sasso E., Delsoldato S., Negrotti A., Mancia D. Reversible valproate-induced extrapyramidal disorders. Epilepsia. 35:1994;391-393
48. Shill H.A., Fife T.D. Valproic acid toxicity mimicking multiple system atrophy. Neurology. 55:2000;1936-1937
49. Guerrini R., Belmonte A., Canapicchi R., Casalini C., Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia. 39:1998;27-32
50. Cotariu D., Zaidman J.L. Valproic acid and the liver. Clin Chem. 34:1988;890-897
51. Gerber N., Dickinson R.G., Harland R.C., Lynn R.K., Houghton L.D., Antonias J.L., et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr. 5:1979;142-144
52. Bohan T.P., Helton E., McDonald I., König S., Gazitt S., Sugimoto T., et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 56:2001;1405-1409
53. McGarry J.D., Foster D.W. An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Research. 17:1976;277-281
54. Beauchamp J., Olson K. Valproic acid overdoses: a retrospective study comparing serum drug levels and the incidence of adverse outcomes. J Toxicol Clin Toxicol. 37:1999;637-638
55. Lejonc J.L., Elkharrat D., Lapandry C., Leblanc J.-P., Robert R., Saint-Martin J., et al. Épuration digestive lors des intoxications aiguës. Rean Urg. 2 bis:1993;169-175
56. Tank J.E., Palmer B.F. Simultaneous "in series" hemodialysis and hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate acid overdose. Am J Kidney Dis. 22:1993;341-344
57. De Vivo D.C., Bohan T.P., Coulter D.L., Dreifuss F.E., Greenwood R.S., Nordli R.S., et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 39:1998;1216-1225